PCL

본문 바로가기

팝업레이어 알림

팝업레이어 알림이 없습니다.
pcl

company
Multi-immune source technology-based platform capable of diagnosing various diseases
Company Intro

PCL Inc., possessing the original technology on multiplex immunodiagnosis, specializes in the in vitro diagnosis medical device. ​
Since its establishment in 2008, we succeeded in commercializing the world's first high-risk viral blood screening multiplex immunodiagnostic product
based on our original technology.

Furthermore, our company succeeded in commercializing highest class and large in vitro diagnostic medical device equipments in the IVD sector for the first time in Korea, becoming an in vitro diagnostic company that leads the existing single immunodiagnostic market into a multiplex immunodiagnostic market.

  • Multiplex IVD PRODUCTS
    Mass Blood Screening
  • Multiplex IVD PRODUCTS
    POCT
  • Covid-19 Total Solution
  • PLATFORM SERVICES
We have developed a platform for diagnosing various diseases based on multiple immune technologies and provide various solutions.
PCL CI

"My hope is to make the fruits of medical innovation accessible to more people globally regardless of their level of income, nationality, or background."

김소연 대표이사

Soyoun Kim

PCL, Inc. CEO
"My hope is to make the fruits of medical innovation accessible to more people globally regardless of their level of income, nationality, or background."
The main reason I stepped out of a stable career in academia to start PCL in a field as fiercely competitive as medical devices is the strong market potential our technology showed. Although the immuno-diagnostics market has been around for a while, innovation is slow, and breakthroughs are, if anything, rare. For example, EIA technology, which PCL specializes in, was first developed 46 years ago and remains standard in an industry estimated to be worth 30 trillion US dollars globally.
Within the field of EIA technology, a US-based company named Abbott has been able to develop techniques that enhance the sensitivity of medical diagnostics in line with government regulations, namely CLIA (Clinical Laboratory Improvement Amendments). In spite of these improvements, it has been hard to get the sensitivity of medical testing devices up to a point where multiple illnesses can be diagnosed at once (known as multiplex diagnosis). 
As a Dongguk University professor, I leveraged research on AIDS transmission I conducted as a PhD candidate at Cornell to create a system for multiplex diagnosis based on aptamer-based protein biochips which are then analyzed for disease detection. The result of this work is none other than the 3D SG CAP solution (3D Sol-gel Capturing System, Multiplex Immunodiagnostic Platform), which can diagnose various diseases simultaneously while keeping the biomarker stable and integrated within the biochip. ​
Our solution has been reviewed by the nationally designated research laboratories of over thirty countries across the world where it has been registered and patented. PCL was founded based on such original technology which we co-developed with German-based Scienion AG. Since its introduction in a popular web-based American magazine back in 2008, the 3D SG CAP solution has made much headway as a game-changer in immuno-diagnostics.
Recently, PCL has reached a major milestone by acquiring multiplex immuno-diagnosis licenses for high-risk viruses in both Europe and South Korea, thus making us a leading player in the industry. The team at PCL is working tirelessly to pave the way for more enhancements in in-vitro diagnostics. We will not stop in our mission to make this premium technology accessible to more people in the world regardless of income or background. It is thus in this spirit of goodwill that I ask for all your support and encouragement. Thank you. ​
  • Founder, CEO, PCL​
  • Professor of Korea University Convergence Research Institute​
    Professor of Biomedical Engineering, Dongguk University​
  • Member of the Mechanical Materials Expert Committee of the National Science and Technology Council ​
  • Associate of the Korean Medical Technology Hallym Institute​
  • Member of PM Steering Committee, Medical Device Division, Korea Health Industry Promotion Agency​
  • Cornell Univ. Biochemistry Ph.D / Department of Chemistry, Korea University​​
  • LG Life Science Diagnosis / Biochip Technology Research Institute​
  • Registered and applied for 37 domestic and foreign patents including Sol-gel original patents and 91 ​ internationally recognized papers
  • Conducted international joint research with 19 institutions, including the US, Europe, Japan, and China, ​ and conducted 22 national tasks for technology development​
  • Received the Minister of Technology Award at the Korea Technology Awards and 11 other awards including, but ​ not limited to the Ministry of Health and Welfare, the Ministry of Environment, and the Excellent Research Award from Seoul.​
  • 25 successful technology transfer and technical guidance​
  • Participated in Korea-US, Korea-Africa and Korea-Bulk Economic Missions (MOU with local company)​ ​